Street taps Epocrates for research

Share this article:

The research arm of investment banking firm Goldman Sachs will look to promote Epocrates' marketing research services. Financial terms of the three-year agreement were not disclosed.

Hudson Street, a Goldman Sachs business, will seek to connect Epocrates to buyside investors and portfolio managers for use in investigating potential pharma and biotech investments.

“We have a highly targeted panel that they can reach,” said Kirk Loevner, Epocrates chairman and chief executive officer.

Epocrates claims 500,000 active clinician users in its subscriber base. Of those, 200,000 are active US physicians, and 145,000 of those have opted into the marketing research service.

Epocrates, also known for its clinical information and decision support tools, already works with about 150 marketing research firms. They are drawn to the vendor's ability to tap into its physician panel, by specialty and by geography, and get answers to surveys. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?